Xu et al. investigated the effects of GSDMD, the principal executioner of pyroptosis downstream of CASP1, 4, 5, and 11, in NAFLD patients and multiple animal models of NASH [47]. Here, GSDMD is linked to metabolic dysfunction-associated steatotic liver disease.